India Osteoarthritis Therapeutics Market Report and Forecast 2025-2034

The India osteoarthritis therapeutics market was valued at USD 382.20 Million in 2024, driven by factors such as increasing healthcare awareness, rising osteoarthritis prevalence, and improvements in treatment options across the region. The market is expected to grow at a robust CAGR of 5.40% from 2025 to 2034, with projected values reaching USD 646.69 Million by 2034. This growth reflects the expansion of healthcare infrastructure, advancements in therapeutics, and a growing demand for effective osteoarthritis treatments across the country.

India Osteoarthritis Therapeutics Market Overview

Osteoarthritis therapeutics encompass a range of treatment approaches, including analgesics, nonsteroidal anti-inflammatory drugs, physical therapy, lifestyle modifications, and surgical options, to alleviate joint pain, enhance mobility, and slow disease progression. In India, the osteoarthritis therapeutics market is poised to grow at a CAGR of 5.40% during the forecast period of 2025-2034, due to the increasing elderly population, sedentary lifestyles, obesity, and greater awareness of early diagnosis.

India Osteoarthritis Therapeutics Market Growth Drivers

High Osteoarthritis Prevalence to Accelerate Therapeutics Market Growth in India

A major growth driver in the market in India is the increasing prevalence of osteoarthritis, particularly among the aging and obese population. According to a study published by the National Institutes of Health (NIH) in March 2024, multiple studies across India reported osteoarthritis prevalence rates ranging from 20% to 40%. This significant and growing disease burden is expected to boost demand for effective treatment solutions, thereby driving sustained market expansion in the coming years.

India Osteoarthritis Therapeutics Market Trends

Some of the notable trends include a rising emphasis on non-opioid pain relief for osteoarthritis.

Increasing Focus on Non-Opioid Pain Relief for Osteoarthritis in India

A significant trend in the market is the growing emphasis on non-opioid treatments for pain relief. In April 2025, Sun Pharma and Israel-based Moebius Medical Limited announced the publication of MM-II’s Phase 2b clinical trial results, highlighting the potential of a novel, non-opioid injection to deliver long-lasting pain relief and protect cartilage in osteoarthritis patients. As the market looks for alternatives to traditional treatments, innovations like MM-II are expected to play a crucial role in shaping the future of osteoarthritis management, ultimately contributing to market growth.

India Osteoarthritis Therapeutics Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Hip Osteoarthritis
• Spinal Osteoarthritis
• Knee Osteoarthritis
• Hand Osteoarthritis
• Others

Market Breakup by Drug Class

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Other Analgesics
• Corticosteroids
• Hyaluronic Acid Injections
• Others

Market Breakup by Dosage Form

• Tablets and Capsules
• Injections
• Creams and Gels
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Topical

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

India Osteoarthritis Therapeutics Market Share

NSAIDs to Account for a Significant Share for Segmentation by Drug Classes

The market, based on drug class, is divided into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, other analgesics, hyaluronic acid injections, and others. NSAIDs are expected to dominate due to their proven efficacy in pain and inflammation management. Their accessibility, affordability, and role as a primary line of treatment make them the most utilized drug category in osteoarthritis therapeutics across the Indian pharmaceutical landscape.

Leading Players in the India Osteoarthritis Therapeutics Market

The key features of the market report comprises epidemiology, clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Sun Pharmaceutical Industries Ltd

Headquartered in Mumbai, India, Sun Pharmaceutical Industries Ltd was established in 1983. The company is actively involved in the osteoarthritis therapeutics market, notably through its MM-II candidate. This treatment has shown promising results in clinical trials, offering durable pain relief for knee osteoarthritis patients. The Phase 2b study demonstrated significant improvements, positioning MM-II as a potential alternative to existing treatments.

Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories, established in 1984 and headquartered in Hyderabad, India, is a leading pharmaceutical company. In the osteoarthritis market, it has launched Hyalosyn, an intra-articular sodium hyaluronate injection aimed at providing relief for knee joint stiffness and immobility. Developed in collaboration with Gland Pharma, Hyalosyn addresses the growing demand for arthritis therapies in India, positioning Dr. Reddy’s as a key contributor to the market.

Cipla Ltd

Cipla Limited, established in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company. It has been actively involved in the India osteoarthritis therapeutics market, received approval for its generic version of Diclofenac sodium topical gel (1%), a therapeutic equivalent to Voltaren gel. This non-steroidal anti-inflammatory drug (NSAID) provides pain relief for osteoarthritis of joints such as the knees and hands, catering to the growing demand in India for affordable treatments.

Zydus Lifesciences Ltd

Headquartered in Ahmedabad, India, and established in 1952, Zydus Lifesciences Limited has strengthened its presence in the market with the USFDA approval for its Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in February 2025. Indicated for osteoarthritis and rheumatoid arthritis, this formulation helps manage symptoms while reducing gastrointestinal risks. Produced at its Ahmedabad facility, the approval reflects Zydus's expanding therapeutic portfolio and growing global and domestic influence in musculoskeletal treatment solutions.

Other key players in the market include Aurobindo Pharma Ltd, Troikaa Pharmaceuticals Ltd, Meril Life Sciences Pvt. Ltd, and Lupin Ltd

Key Questions Answered in the India Osteoarthritis Therapeutics Market Report

• What was the India osteoarthritis therapeutics market value in 2024?
• What is the India osteoarthritis therapeutics market forecast outlook for 2025-2034?
• What are the major factors aiding the India osteoarthritis therapeutics market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major India osteoarthritis therapeutics market trends?
• Which type is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which dosage form is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which end user is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the India osteoarthritis therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.